C1328813||Metabolomic
C0162448||glycerophospholipid
C0021368||inflammation
C0332293||treated with
C0003211||non-steroidal anti-inflammatory drugs
C0024432||RAW264.7 cells
C0877853||(1)H NMR
C0008562||U-HPLC
C0877853||Non-destructive proton nuclear magnetic resonance ((1)H NMR) spectroscopy
C0008562||ultra-performance liquid chromatography
C0008562||U-HPLC
C0025663||methods
C1328813||metabolic profiling
C0162448||glycerophospholipids
C0162448||glycerophospholipids
C0024432||RAW264.7 cells
C0021368||inflammation
C0033325||prognosis
C0936012||Analysis
C0877853||(1)H NMR
C3161035||models
C0877853||(1)H NMR
C0003209||anti-inflammatory drugs
C1328813||metabolic profiling
C0162448||glycerophospholipids
C0162448||glycerophospholipids
C0008562||U-HPLC
C2603343||study
C0005516||biomarkers
C1959616||phosphatidylcholine
C1959616||phosphatidylcholine
C0005516||biomarkers
C0877853||(1)H NMR
C0008562||U-HPLC
C1148554||determination
C0005516||biomarkers
C1720914||sample preparation steps
C0870883||metabolite
C0162448||glycerophospholipids
C0021368||inflammation
C0877853||(1)H NMR spectroscopy
C0008562||U-HPLC
C1328813||metabolic profiling
C0162448||glycerophospholipids
C0021368||inflammation
C0011900||diagnosis
C0033325||prognosis
C0021368||inflammation
C0242656||progression